Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia Technologies

0.93 EUR-0.32 %25.9, 11.25
2,236 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-0.32 %
-13.29 %
-48.74 %
-46.07 %
-62.53 %
-66.32 %
-76.20 %
-
-81.56 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
34.91M EUR
Turnover
9.79K EUR
P/E (adj.) (26e)
-2.59
EV/EBIT (adj.) (26e)
-2.85
P/B (26e)
3.01
EV/S (26e)
14.19
Dividend yield-% (26e)
-
Coverage
Recommendation
Reduce
Target price
1.10 EUR
Updated
31.08.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 31.08.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
In the presentation Jukka Tapaninen: “we have not failed in anything”. Situation: revenue hasn’t grown in years and the share price is down over -80% in a few years. ok.
9/8/2026, 8:55 AM
by Umpi
24
Greetings to the Aiforia thread! Antti and I shot a video about Aiforia today, as the company is generating a lot of discussion. Below is the link to the video as well as to today’s Stock Investor’s Week presentation. “Aiforia, which develops AI-based image recognition, has a long...
9/8/2026, 1:02 PM
by Mikael Maijala
21
LinkedIn Home - 2026 World Medical Innovation Forum | Aiforia Technologies Aiforia's CEO, Jukka Tapaninen, will be speaking on an expert panel at the World Medical Innovation Forum taking place in Boston on September 22. The panel features industry leaders discussing how AI technologies...
9/17/2026, 10:22 AM
by Salvelinus
17
Someone wanted to get rid of them, but someone else was happy to take them, doesn’t directly match anyone’s holdings. From Kauppalehti’s breaking news: Aiforia Technologies: Block trade at 16:25. The trade involved 182,000 shares at 0.88 euros each, with a total value of 160,160 ...
9/17/2026, 3:24 PM
by NukkeNukuttaja
13
Thank you model portfolio, thank you, we’re finally taking off. I didn’t think I’d see this day, thank you, thank you, thank you.
9/2/2026, 4:18 PM
by Salvelinus
11
Quite a peculiar comment, and there seems to be a bit of an attitude problem. The CEO has completely failed in growing shareholder value since the IPO, as written above—meaning 20% of the investment is left, along with massive dilutions from new share issues. At the IPO, positive...
9/8/2026, 10:04 AM
by kovatuotto
10
Sectra has a large number of partners. Aiforia is just one of them. To my knowledge, Aiforia hasn’t announced the conquest of that region in southern France, but rather the major Paris area. Oh wait, there was also the University of Nantes, but that’s not in the south either.
9/21/2026, 1:39 PM
by Vino Pino
9
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release24.09.2026, 09.15

Aiforia Technologies Plc: Share subscriptions based on stock options 2016B

Aiforia Technologies
Analyst Comment09.09.2026, 06.35

Børsurougen | Sundhed & Vækst og M&A 8.9.2026

Børsinvestorens ugentlige temaer Sundhed samt Vækst & M&A kan ses på inderesTV.

Aiforia TechnologiesTerveystaloOrionRelais GroupAspo
Modelportfolio: Vi har ryddet ud i den mislykkede Aiforia-investering i porteføljen
Research02.09.2026, 09.00 by
Juha Kinnunen, Atte Riikola, Rauli Juva

Modelportfolio: Vi har ryddet ud i den mislykkede Aiforia-investering i porteføljen

I vores vækstinvestering med høj risiko udeblev væksten, hvilket ødelagde vores oprindelige investeringsteser.

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research02.09.2026, 08.08

Aiforia Technologies: H1'26 review: costs above expectations; est. & PT chg. - NuWays AG Research

Aiforia published its H1'26 report last Friday. Revenue of € 0.75m (-46% yoy) was already knownfrom the July profit warning, which we attributed to the absence of onboarding revenue and a slower than expected usage ramp up of existing clinical clients...

Aiforia Technologies
Aiforia H1'26: Still a long way to go before reaching profitability
Research31.08.2026, 13.26 by
Antti Siltanen, Antti Luiro

Aiforia H1'26: Still a long way to go before reaching profitability

Earnings fell short of our expectations due to both a one-off expense and a more permanent increase in the cost structure.

Aiforia Technologies
Aiforia, Webcast, Q2'26
Webcast28.08.2026, 09.00

Aiforia, Webcast, Q2'26

Aiforia Technologies
Regulatory press release28.08.2026, 08.00

Aiforia’s Half-Year Financial Report January-June 2026: Financing arrangements and new customers support future growth, revenue remained below the comparison period's level

Aiforia Technologies
Aiforia lands new partnership in breast cancer diagnostics
Analyst Comment26.08.2026, 09.59 by
Antti Siltanen

Aiforia lands new partnership in breast cancer diagnostics

The new partnership brings predictive risk profiling into diagnostics and can reduce the need for expensive genetic tests.

Aiforia Technologies
Aiforia H1'26 preview: Profit warning increased concerns about commercial progress
Analyst Comment26.08.2026, 12.00 by
Antti Siltanen

Aiforia H1'26 preview: Profit warning increased concerns about commercial progress

Contract delays caused H1 revenue to collapse to 0.75 MEUR and increased concerns about commercial performance.

Aiforia Technologies
Press release25.08.2026, 08.30

Aiforia and Stratipath partner to expand access to AI-driven precision diagnostics in oncology

Aiforia Technologies
Press release19.08.2026, 07.00

Aiforia to publish January–June 2026 Half-Year Financial Report on August 28, 2026

Aiforia Technologies
Aiforia secured a 20 MEUR financing agreement with the EIB
Analyst Comment03.08.2026, 08.19 by
Antti Siltanen, Antti Luiro

Aiforia secured a 20 MEUR financing agreement with the EIB

The loan arrangement secures financing for the coming years, provided the business develops favorably.

Aiforia Technologies
Regulatory press release31.07.2026, 17.00

Aiforia and the European Investment Bank have signed an agreement for EUR 20 million venture debt financing

Aiforia Technologies
Regulatory press release24.07.2026, 10.00

Aiforia Technologies Plc – Managers’ Transactions – Jukka Tapaninen

Aiforia Technologies
Third party research23.07.2026, 09.04

Aiforia Technologies: Aiforia H1 profit warning triggers downgrade to HOLD - NuWays AG Research

Aiforia issued a profit warning with H1'26 revenues coming in at a mere € 0.75m, down from € 1.4m in H1'25 (-46% yoy), against our expectation of roughly doubling yoy, following last year's strong Clinical momentum (organic growth of +65%). At the same...

Aiforia Technologies
Aiforia: We diagnose a growth deficiency
Research23.07.2026, 09.25 by
Antti Siltanen

Aiforia: We diagnose a growth deficiency

The ongoing uncertainty regarding growth is causing us to take a negative view of the risk-reward ratio.

Aiforia Technologies
Aiforia's H1 revenue was surprisingly subdued
Analyst Comment22.07.2026, 08.05 by
Antti Siltanen

Aiforia's H1 revenue was surprisingly subdued

The conversion of customer wins into revenue continues to be slow.

Aiforia Technologies
Regulatory press release21.07.2026, 17.40

Inside information, profit warning: Aiforia's revenue developed below the estimates during January–June 2026

Aiforia Technologies
Regulatory press release06.07.2026, 08.00

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release06.07.2026, 08.00

Aiforia Technologies Plc – Managers’ Transactions – Johan Lundin

Aiforia Technologies